Microbiome-Targeting Therapy MaaT033 Continues to Show Promise in Final Phase 1 Readout

Phase 1b data show oral microbiome therapy MaaT033 slows ALS progression and is well tolerated, supporting future phase 2 development efforts.:

Source: Neurology Read More